Bioventus Inc. (BVS) P/E Ratio History
Fairly ValuedTrading at 31.8x, near 5Y avg of 29.3x · 86th percentile · In line with own history · Data 2021–2026
Loading P/E history...
P/E Ratio Analysis
As of July 6, 2026, Bioventus Inc. (BVS) trades at a price-to-earnings ratio of 31.8x, with a stock price of $10.48 and trailing twelve-month earnings per share of $0.41.
The current P/E is roughly in line with its 5-year average of 29.3x. Over the past five years, BVS's P/E has ranged from a low of 21.0x to a high of 58.5x, placing the current valuation at the 86th percentile of its historical range.
Compared to the Healthcare sector median P/E of 23.8x, BVS trades at a 33% premium to its sector peers. The sector includes 231 companies with P/E ratios ranging from 0.0x to 195.3x.
Relative to the broader market, BVS commands a significant premium over the S&P 500 median P/E of 25.6x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our BVS DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
BVS Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
BVS P/E vs Peers
Orthopedics, spine, and sports medicine peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $7B | 32.2 | - | -22% | |
| $11B | 20.4Lowest | 0.66Best | +423%Best |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
BVS Historical P/E Data (2021–2026)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Period End | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2026 Q1 | Mar 28 2026 | $8.94 | $0.41 | 21.8x | -26% |
| FY2025 Q4 | Dec 31 2025 | $7.44 | $0.33 | 22.8x | -22% |
| FY2025 Q3 | Sep 27 2025 | $6.66 | $0.11 | 58.5x | +100% |
| FY2021 Q4 | Dec 31 2021 | $14.49 | $0.46 | 31.5x | +8% |
| FY2021 Q3 | Oct 02 2021 | $14.33 | $0.54 | 26.4x | -10% |
| FY2021 Q2 | Jul 03 2021 | $16.51 | $0.72 | 22.8x | -22% |
| FY2021 Q1 | Apr 03 2021 | $15.23 | $0.72 | 21.0x | -28% |
Average P/E for displayed period: 29.3x
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
5+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
BVS — Frequently Asked Questions
Quick answers to the most common questions about buying BVS stock.
What is BVS's P/E ratio?
Bioventus Inc. (BVS) trailing twelve-month P/E ratio is 31.8x, based on TTM diluted EPS of $0.41. The 5-year average P/E is 29.3x and the historical range spans 21.0x to 58.5x.
Is BVS stock overvalued or undervalued?
BVS trades at 31.8x P/E, near its 5-year average of 29.3x. The 86th percentile ranking within the 21.0x–58.5x historical range places valuation within normal bounds.
Is BVS stock expensive?
BVS is fairly valued relative to its own history. The current P/E of 31.8x is near the 5-year average of 29.3x (86th percentile of historical range).
What is BVS's historical P/E range?
Over the past 5 years, BVS's P/E ratio has ranged from 21.0x to 58.5x, with a median of 22.8x and an average of 29.3x. The current P/E of 31.8x places the stock at the 86th percentile of this range. Full historical data spans 2021–2026.
How does BVS's P/E compare to the S&P 500?
BVS trades at 31.8x P/E versus the S&P 500 median of 25.6x. The 24% premium to the market typically reflects higher expected earnings growth or quality.
How does BVS's valuation compare to Healthcare peers?
Bioventus Inc. P/E of 31.8x compares to the Healthcare sector median of 23.8x. The premium reflects expected growth above peers or stronger fundamentals. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.
What is BVS's PEG ratio?
BVS PEG ratio is N/A, based on a P/E of 31.8x and EPS growth of 163.5%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.
What is BVS's earnings yield?
BVS earnings yield is 3.15%, the inverse of its 31.8x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.